ACM
MYGN icon

Apex Capital Management’s Myriad Genetics MYGN Stock Holding History

Apex Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-40,903
Closed -$1.1M – 240
2013
Q2 		$1.1M Buy
+40,903
New +$1.19M 0.05% 159

Other funds holding MYGN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
MNA
Manning & Napier Advisors Fairport, New York $7.09B AUM 17.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MCM
Munder Capital Management Birmingham, Michigan $13.4B AUM 18.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.28B AUM 23.15% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Apex Capital Management's MYGN Position: Q3 2013 in Review

Apex Capital Management sold out of Myriad Genetics (MYGN) in Q3 2013, closing a stake of 40,903 shares — an estimated $1.1M sold.

Apex Capital Management first reported a position in MYGN in Q2 2013 and held it in 1 quarter. The position peaked at $1.1M in Q2 2013. 267 funds tracked by Wall St. Rank hold MYGN as of Q3 2013.

  • Apex Capital Management reported no remaining Myriad Genetics position as of Q3 2013 after selling out during the quarter.
  • Apex Capital Management sold 40,903 Myriad Genetics shares in Q3 2013, an estimated $1.1M.
  • Apex Capital Management first reported a position in Myriad Genetics in Q2 2013 and held it in 1 quarter.
  • Apex Capital Management's Myriad Genetics position peaked at $1.1M in Q2 2013.
  • 267 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2013.

Based on Apex Capital Management's 13F filing for Q3 2013, filed 17 Oct 2013.